Table 2.
Intraoperative and postoperative data of TACE + PVE and PALPP groups were compared
| Index | TACE + PVE group | PALPP group | P |
|---|---|---|---|
| Data of first step | (n = 12) | (n = 17) | |
| Preoperative variables | |||
| AST (U/L) (median [IQR]) | 47.0 (32.8, 72.5) | 55.0 (34.5, 83.5) | 0.72 |
| ALT (U/L) (median [IQR]) | 31.5 (24.5, 47.0) | 42.0 (17.5, 72.5) | 0.83 |
| AFP (> 20 μg/L) (%) | 10 (83.3) | 11 (64.7) | 0.41 |
| TB (μmol/L) (median [IQR]) | 13.1 (11.3, 20.9) | 20.1 (14.6, 25.7) | 0.03 |
| Postoperative complications (Clavien Dindo) (%) | |||
| > Grade II | 1 (8.3) | 2 (11.8) | 1.00 |
| Details | Liver failure ( n = 1, 8.3%) | Perioperative mortality (n = 1, 5.9%), pleural effusion (n = 1, 5.9%) | |
| Data of second step | (n = 7) | (n = 13) | |
| Second step | Second step (n = 7, 58.3%) | Second step (n = 13, 76.5%) | 0.42 |
| Reasons for not proceeding to second step hepatectomy | Total:n = 5 (41.7%), Tumor progression (n = 2, 11.8%), Liver failure (n = 1, 8.3%), insufficient hypertrophy of FLR (n = 2, 16.7%) | Total:n = 4 (23.5%), Tumor progression (n = 2, 11.8%), Liver failure (n = 1, 5.9%), loss to follow-up (n = 1, 5.9%) | |
| Second step variables | |||
| AST (U/L) (median [IQR]) | 30.0 (25.0, 37.0) | 49.0 (27.5, 87.5) | 0.19 |
| ALT (U/L) (median [IQR]) | 24.0 (18.0, 47.0) | 42.0 (23.0, 66.5) | 0.23 |
| AFP (> 20 μg/L) (%) | 5 (71.4) | 7 (53.8) | 0.64 |
| TB (μmol/L) (median [IQR]) | 16.6 (13.3, 18.5) | 18.9 (12.3, 31.3) | 0.38 |
| Second step variables | |||
| Operation time (min) (median [IQR]) | 300.0 (205.0, 350.0) | 285.0 (245.0, 295.0) | 0.38 |
| Pringle maneuver (min) (median [IQR]) | 0.0 (0.0, 45.0) | 12.0 (0.0, 29.0) | 0.54 |
| Blood transfusion (%) | 5 (71.4) | 10 (83.3) | 0.60 |
| Intraoperative blood loss (ml) (median [IQR]) | 700.0 (200.0, 1000.0) | 800.0 (450.0, 1100.0) | 0.84 |
| Type of hepatectomy (%) | NA | ||
| Right hepatectomy | 4 (57.1) | 2 (15.4) | |
| Right trisegmentectomy | 1 (14.3) | 9 (69.2) | |
| Palliative hepatectomy | 0 (0.0) | 2 (15.4) | |
| 2 segmental liver resection/tumor resection | 2 (28.6) | 0 (0.0) | |
| Sceond step complications (Clavien Dindo) (%) | |||
| > Grade II | 0 (0.0) | 6 (46.2) | 0.05 |
| Details | Abdominal bleedinga (n = 1, 7.7%), Liver failure (n = 1, 7.7%), Intestinal obstruction (n = 1, 7.7%), pneumothorax (n = 1, 7.7%), Thoracic effusion requires puncture and drainage (n = 3, 23.1%) | ||
| R0 (%) | 7 (100.0) | 11 (84.6) | 0.52 |
| Death 90 days after surgery (%) | 0 (0.0) | 2 (15.4) | |
| Cuase of death | Liver failure (n = 1, 7.7%), Tumor progression (n = 1, 7.7%) | ||
| Postoperative tumor recurrence (%) | 3 (42.9) | 11 (84.6) | 0.12 |
| Treatment after recurrence | (n = 3) | (n = 11) | |
| Rehepatectomy (%) | 0 (0.0) | 2 (18.2) | |
| Ablation (%) | 1 (33.3) | 1 (9.1) | |
| TACE (%) | 1 (33.3) | 2 (18.2) | |
| Radiotherapy (%) | 0 (0.0) | 1 (9.1) | |
| Chemotherapy (%) | 0 (0.0) | 1 (9.1)b | |
| Targeted therapy (%) | 0 (0.0) | 0 (0.0) | |
| Chemotherapy + Targeted therapy (%) | 1 (0.0)c | 0 (0.0) | |
| Supportive treatment (%) | 0 (0.0) | 4 (36.4) | |
aAbdominal bleeding requires secondary surgical hemostasis
bChemotherapy (tegafur)
cChemotherapy (FOLFOX) + Targeted therapy (sorafenib)